← Back to Clinical Trials
Recruiting Phase 1 NCT07269301

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

Trial Parameters

Condition Hepatic Impairment
Sponsor Pfizer
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 26
Sex ALL
Min Age 18 Years
Max Age 74 Years
Start Date 2025-12-29
Completion 2027-02-23
Interventions
PF-07328948

Brief Summary

The purpose of this study is to understand the effects of decreased liver function on the study medicine (PF-07328948). People with decreased liver function may process the study medicine differently from healthy people. Study is seeking participants who: * Are between 18 and 75 years of age. * Have a BMI (body mass index) of 17.5 to 40 kg/m2, inclusive, and a total body weight of more than or equal to 45 kilograms or 99 pounds. Participants will take the study medicine as a tablet once at the study clinic and then will stay onsite for about 6 days. During this time, the study team will check for the participant's treatment experience and take some blood samples to test the level of PF-07328948. This will help understand if certain level of decreased liver function could affect the study medicine being processed in the body.

Eligibility Criteria

Inclusion Criteria: * Male or female of nonchildbearing potential, between the ages of 18 (inclusive) and 75 years, at the screening visit. * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * BMI of 17.5 to 40.0 kg/m2 (inclusive), and a total body weight ≥45 kg (99 lb). * Group 4 only: at screening, no clinically relevant abnormalities identified by a detailed medical history, physical exam, including blood pressure and pulse rate measurement, ECG and clinical laboratory tests. * Group 4 only: no known or suspected hepatic impairment and meet the criteria based on screening laboratory liver function tests. * Groups 1, 2 \& 3 only: stable hepatic impairment that meets criteria for Class A, B, or C of the Child-Pugh classification with no clinically significant change in disease status within 28 days before screening. * Groups 1, 2 \& 3 only: stable concomitant medications for the management of

Related Trials